Acne

Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit, characterized by excess sebum production, follicular hyperkeratinization, Cutibacterium acnes colonization, and inflammation ^[17]D5. It presents with comedones (open and closed), papules, pustules, nodules, and cysts, often leading to scarring and dyspigmentation ^{[14]B3b[17]D5}. Synonyms include common acne, and when persisting beyond age 25, acne tarda (adult acne, post-adolescent acne) ^[16]D5. Acneiform drug eruptions are a separate entity that mimics acne vulgaris ^[11]D5.

Clinical Classification

Acne vulgaris is classified by predominant lesion type and severity ^[16]D5:

Age-Based Classification

Pediatric acne is categorized by age and pubertal status: neonatal (birth-6 weeks), infantile (6 weeks-1 year), preadolescent (1-7 years), and adolescent (12-19 years) ^[4]A1c. Adult acne, or acne tarda, is defined as acne occurring at age ≥25 years, affecting both sexes ^[16]D5. Acne tarda is further divided into non-inflammatory (acne comedonica tarda) and inflammatory (acne papulopustulosa tarda) subtypes ^[16]D5.

Acneiform Drug Eruptions

Drug-induced acneiform eruptions differ from acne vulgaris by their monomorphic inflammatory lesions, involvement of atypical sites (e.g., trunk, extremities), and occurrence outside the typical age range ^[11]D5. Common culprits include epidermal growth factor receptor inhibitors and Janus kinase inhibitors ^[11]D5.

Clinical Significance

Acne vulgaris is one of the most common skin diseases worldwide, with a prevalence of up to 85% in adolescents aged 15-18 years ^[16]D5. In women, 55% have some form of acne, with 27% having clinical acne ^[14]B3b. The condition carries substantial psychosocial burden, including reduced quality of life, depression, and increased suicide risk ^[16]D5.

The distinct pathophysiologic mechanisms driving these clinical subtypes are explored in the following section.

Pearl: Acne vulgaris is defined by its lesion types (comedones, inflammatory lesions) and chronic course; distinguishing true acne from acneiform drug eruptions is critical as management differs, acneiform eruptions often respond to symptomatic treatment without discontinuing the causative drug ^[11]D5.

Having defined acne as a chronic inflammatory disease of the pilosebaceous unit, the pathogenic cascade begins with androgen-driven sebaceous hyperactivity and culminates in a dysregulated immune response that transforms a commensal microbe into a proinflammatory trigger. The sequence involves four interdependent steps: hyperseborrhea, follicular hyperkeratinization, Propionibacterium acnes colonization, and inflammation, each modulated by genetic susceptibility and environmental exposome factors ^[31]D5[39]D5.

The Four-Pillar Cascade

1. Androgen-driven sebum overproduction. Androgens (testosterone, dihydrotestosterone) and insulin-like growth factor-1 (IGF-1) activate sebocyte lipogenesis through the PI3K/Akt/SREBP-1 pathway, with AMPK serving as a negative regulator ^{[23]A1b[28]D5}. The result is increased sebum excretion and altered lipid composition, which creates a favorable environment for P. acnes proliferation ^[29]D5. A 30-50% reduction in sebum is projected to achieve a 50% reduction in acne lesion counts ^[29]D5.

2. Follicular hyperkeratinization. Androgens and retinoid deficiency promote abnormal desquamation of follicular keratinocytes, leading to microcomedone formation, the precursor of all acne lesions ^{[24]A1b[31]D5}. The "comedo switch" hypothesis posits that aberrant differentiation of sebaceous progenitor cells drives this process, involving Wnt, ErbB, and FGFR2 signaling ^[28]D5.

3. P. acnes colonization and dysbiosis. P. acnes is a dominant lipophilic commensal in sebaceous follicles. Westernization and lifestyle changes may disrupt the cutaneous microbiota, allowing overgrowth of certain phylotypes and transforming a harmless commensal into an opportunistic pathogen ^[27]D5. However, inflamed lesions can occur without detectable P. acnes, suggesting that inflammation may be initiated by other triggers ^[40]D5.

4. Inflammation and immune dysregulation. P. acnes activates toll-like receptor 2 (TLR-2) on keratinocytes and monocytes, triggering NF-κB and AP-1 pathways and releasing proinflammatory cytokines: interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and matrix metalloproteinase-9 (MMP-9) ^{[21]A1b[23]A1b}. Crucially, patients with acne have a defect in IL-10 secretion from CD14+ monocytes, impairing the anti-inflammatory counterbalance and reducing phagocytic clearance of P. acnes ^[30]B3b. This creates a self-perpetuating proinflammatory milieu that drives papules, pustules, and nodules.

Genetic and Exposome Modifiers

Family studies and genome-wide association studies have identified loci implicating pathways in sebaceous biology, inflammation, and androgen metabolism ^[32]B3b. Rare syndromes featuring acne-like lesions (e.g., FGFR2-related disorders) further highlight these pathways ^[28]D5. Exposome factors, including high glycemic-load diet, psychological stress, pollutants, and certain medications, can amplify each step of the cascade ^{[22]A1b[39]D5}.

Mechanistic Cascade

Pearl: The IL-10 defect in acne patients is a key immunologic vulnerability; therapies that restore IL-10 or enhance phagocytosis may offer novel approaches to break the inflammatory cycle.

From the pathogenic mechanisms of follicular hyperkeratinization, sebum overproduction, and Cutibacterium acnes colonization, the clinical expression of acne emerges in a predictable demographic pattern. Acne vulgaris is nearly universal in adolescence, with a global age-standardized prevalence among 10-24 year-olds of 9790.5 per 100,000 (95% UI 8420.9-11,287.2) in 2021, a significant increase from 8563.4 per 100,000 in 1990 (average annual percentage change 0.43) ^[59]B3b. Moderate-to-severe acne affects approximately 20% of young people ^[42]A1a. In a multiethnic cohort of 13-year-olds, visible acne (Global Evaluation of Acne Severity grade 2-5) was present in 62% of girls and 45% of boys, with moderate-to-severe disease in 14% and 9%, respectively ^[49]B3b. Acne persists beyond adolescence: around 64% of individuals have acne into their 20s and 43% into their 30s ^[42]A1a. The burden is higher in young women than young men (age-standardized prevalence 10,911.8 vs 8,727.8 per 100,000) ^[59]B3b. Regionally, Western Europe has the highest rates, while North Africa and the Middle East have seen the largest increases; high sociodemographic index (SDI) regions have the highest burden, but low-middle SDI regions experienced the most significant rise ^[59]B3b.

Risk Factors

Acne has a strong genetic component, with heritability estimated at 80% in first-degree relatives ^[42]A1a. Earlier and more severe acne occurs in those with a positive family history ^[42]A1a. Pubertal maturity is a key determinant: each advancing puberty stage increases the odds of more severe acne (adjusted odds ratio [aOR] 1.38 in girls, 2.16 in boys) ^[49]B3b. Darker skin colors (Fitzpatrick V-VI) are associated with higher severity (aOR 1.90 in girls, 2.43 in boys) ^[49]B3b. Overweight in boys increases risk (aOR 1.58) ^[49]B3b. Dietary factors remain controversial: a 2005 systematic review found no clear evidence, but one small randomized trial showed low glycemic index diets reduce severity; dairy intake requires further scrutiny ^[42]A1a. Smoking and natural sunlight or poor hygiene are not associated ^[42]A1a. Propionibacterium acnes biofilms are more prevalent in acne lesions (37% vs 13% controls; OR 3.85) ^[54]B3b. Antibiotic treatment reduces Staphylococcus aureus nasal carriage (6.3% vs 15.7%) ^[56]B3b. Acne is strongly associated with hidradenitis suppurativa (prevalence 15.2% vs 2.9%; OR 4.51) ^[55]B3b and with depression (r=0.22) and anxiety (r=0.25) ^[44]B2a. Body dysmorphic disorder symptoms occur in 14-21% of acne patients ^[57]B3b.

Special Considerations

Isotretinoin exposure is associated with a small increased risk of inflammatory bowel disease within 6 months (adjusted OR 1.87; absolute risk difference 2.6 more cases per 10,000 patients), but the 1-year risk is not significantly different from unexposed patients ^[50]B3b. The economic burden is substantial: in the U.S., costs exceed $3 billion annually in treatment and lost productivity ^[42]A1a. Acne vulgaris is underrepresented in Cochrane reviews relative to its disability-adjusted life years (DALYs) ^[46]B2a.

These epidemiological patterns set the stage for the clinical spectrum of acne, which ranges from comedonal to nodulocystic lesions, detailed in the next section.

Pearl: When assessing an adolescent with acne, ask about family history (heritability 80%) and screen for depression, anxiety, and body dysmorphic disorder, these comorbidities are common and often overlooked.

Acne vulgaris is an almost universal condition in younger people ^[42]A1a, but its clinical presentation varies widely by age, sex, and severity. The morphology, distribution, and associated symptoms guide the clinician toward the correct diagnosis and appropriate treatment.

Presenting Symptoms

Patients typically present during adolescence, with onset correlating with pubertal maturity ^[42]A1a. Acne may now appear at a younger age because of earlier puberty ^[42]A1a. The condition is often chronic: it persists into the 20s in around 64% of individuals and into the 30s in 43% ^[42]A1a. Most lesions are asymptomatic, but inflammatory papules and nodules can be tender. Pruritus is not a feature of classic acne; its presence should raise suspicion for Pityrosporum folliculitis ^[72]D5.

Psychosocial symptoms are common. Acne vulgaris has a significant association with depression (r = 0.22, 95% CI 0.17-0.26) and anxiety (r = 0.25, 95% CI 0.19-0.31) ^[44]B2a. Suicidal ideation is more frequent in those with severe compared with mild acne ^[42]A1a. Clinicians should pursue aggressive treatment and consider psychiatric screening or referral ^[44]B2a.

Examination Findings

Lesions are polymorphic and include comedones (open and closed), papules, pustules, nodules, and cysts. In darker skin types, postinflammatory hyperpigmentation (PIH) is a common sequela ^{[42]A1a[65]B2b}. Scarring may develop, particularly in moderate-to-severe disease.

Facial distribution is broad: in adult women, 89.8% have acne involving multiple zones (cheeks, forehead, mandibular area, temples) ^[67]B3b. Truncal acne (chest, back, shoulders) is present in 48.4% of adult women ^[67]B3b and is common in adolescents. Severity varies; moderate-to-severe acne affects around 20% of young people ^[42]A1a. In adult women presenting to a dermatologist, 47.3% had mild or clear/almost clear acne, though many were already on treatment ^[67]B3b.

Phenotypic Variants

Red Flags

• Acne fulminans: sudden onset of ulceronecrotic lesions, especially in adolescent males; may be triggered by isotretinoin ^[66]C4. Systemic signs (fever, arthralgia) occur in a minority (6.7% in one series) ^[66]C4.
• Suicidal ideation: more common in severe acne ^[42]A1a; screen using validated tools such as the Patient Health Questionnaire-2 or -9 before and during isotretinoin therapy ^[71]D5.
• Severe scarring or psychological distress: warrants early aggressive treatment and possible referral.

Atypical Presentations

Pityrosporum folliculitis mimics acne but presents with 1-2 mm monomorphic, pruritic papules and pustules on the forehead extending into the hairline and on the upper back ^[72]D5. Over 75% of affected patients have recently used antibiotics for acne ^[72]D5. It responds to topical or oral azole antifungals, not standard acne therapy ^[72]D5.

Acne excoriée (not directly covered in the provided evidence) is characterized by excoriated lesions from compulsive picking, often in young women with underlying emotional distress.

Recognition of these clinical patterns guides the differential diagnosis and directs further evaluation, as discussed in the next section.

Pearl: The presence of pruritic monomorphic papules along the hairline should prompt a potassium hydroxide preparation to rule out Pityrosporum folliculitis before escalating acne therapy ^[72]D5.

The clinical diagnosis of acne is primarily based on morphology and distribution, but emerging technologies and standardized assessments are refining diagnostic accuracy and expanding access to care.

Clinical Examination as Gold Standard

Acne vulgaris is diagnosed by visual inspection and palpation of the skin. The clinician identifies lesion types (open and closed comedones, papules, pustules, nodules, cysts) and their distribution (face, chest, back, shoulders). No laboratory test is required for diagnosis; histopathology is reserved for atypical presentations. The diagnosis is straightforward in typical cases, but severity grading and lesion counting can vary between examiners, prompting interest in standardized tools.

Teledermatology and Digital Assessment

Teledermatology has grown rapidly and offers a reliable alternative to in-person visits for acne assessment. A pilot reliability study compared patient-taken photographs using the Network Oriented Research Assistant (NORA) application on an iPhone 6 with in-person examination by the same dermatologist ^[79]D5. Among 69 patients (mean age 22.7 years), intraclass correlation coefficients (ICCs) indicated strong agreement between the two methods: total lesion count ICC 0.81, Investigator's Global Assessment (IGA) ICC 0.75, inflammatory lesion count ICC 0.72, noninflammatory lesion count ICC 0.72, and cyst count ICC 0.82 ^[79]D5. These findings support the use of patient-taken photographs as a reliable telehealth platform for acne research and clinical care, particularly for increasing access to dermatologic care ^[79]D5.

A systematic review of 13 studies confirmed that teledermatology for acne is well accepted by patients, especially those in remote areas, and is associated with higher satisfaction due to reduced time and cost ^[82]B2a.

Diagnostic Test Performance

The provided evidence does not report sensitivity, specificity, positive predictive value, or negative predictive value for any diagnostic test for acne. The gold standard remains in-person dermatologist examination. The table below summarizes the reliability data available for teledermatologic assessment.

ICC = intraclass correlation coefficient; gold standard = in-person dermatologist examination.

Dermoscopy and Wood Lamp Examination

Dermoscopy is not specifically addressed in the provided references, but it can aid in distinguishing comedones from other follicular lesions and in assessing post-inflammatory hyperpigmentation. Wood lamp examination may highlight porphyrin fluorescence from Cutibacterium acnes colonization, though its routine diagnostic utility in acne is limited. These tools are more relevant to differential diagnosis and are covered in the subsequent section on Dermatopathology and Laboratory Diagnosis.

Limitations and Future Directions

The diagnostic evidence for acne is largely based on clinical expertise. Teledermatology offers reliable remote assessment, but further studies are needed to validate diagnostic accuracy metrics (sensitivity, specificity) against the gold standard. The digit ratio (2D:4D) has been associated with acne severity in females, suggesting a potential biomarker for prenatal androgen exposure, but it is not a diagnostic test ^[75]B3b.

Pearl: Patient-taken photographs using a standardized smartphone application show strong agreement with in-person examination (ICC 0.81 for total lesion count), making teledermatology a reliable option for acne assessment and follow-up, especially when access to care is limited ^[79]D5.

While the diagnosis of acne vulgaris is established clinically, histopathologic and laboratory studies are not required for routine diagnosis but provide pathogenetic insights and may aid in atypical presentations.

Histopathology

When biopsied, acne lesions show characteristic findings. Comedones are associated with atrophic sebaceous glands, suggesting abnormal differentiation of progenitor cells ^[28]D5. Inflammatory pustules demonstrate significantly higher perivascular and interstitial expression of human neutrophil proteins (HNP) 1-3 compared with uninvolved skin ^[98]B3b. Immunohistochemical studies reveal that cytoplasmic expression of forkhead box transcription factor O1 (FoxO1) is significantly greater in acne lesions, whereas in controls it is predominantly nuclear; both cytoplasmic and nuclear expression of mammalian target of rapamycin (mTOR) are more intense in acne patients ^[100]D5. These findings are not diagnostic but reflect the underlying inflammatory and metabolic pathways.

Laboratory Studies

Serum insulin-like growth factor-1 (IGF-1) levels are elevated in acne patients compared with controls and positively correlate with acne severity ^{[95]B3b[100]D5}. However, IGF-1 measurement is not used for diagnosis in clinical practice. No other laboratory tests are routinely indicated for the diagnosis of acne vulgaris.

Microbiologic Testing

Routine culture or molecular testing for Cutibacterium acnes is not recommended for diagnosis. The organism is part of the normal skin microbiota, and its presence does not distinguish acne from healthy skin.

Diagnostic Algorithm

The workup for acne is purely clinical. The following algorithm summarizes the diagnostic pathway:

Step 1: Obtain a focused history including onset, duration, exacerbating factors, and prior treatments. Step 2: Perform a physical examination noting the presence of comedones (open and closed), inflammatory papules, pustules, nodules, and cysts on the face, chest, and back. Step 3: If comedones and inflammatory lesions are present in a characteristic distribution, the diagnosis of acne vulgaris is confirmed. No laboratory or histopathologic confirmation is required. Step 4: If the presentation is atypical (e.g., monomorphic lesions, absence of comedones, unusual distribution), consider alternative diagnoses such as rosacea , folliculitis , or drug eruptions, and pursue biopsy or other testing as indicated.

Pearl: Acne is a clinical diagnosis; biopsy is reserved for atypical lesions to exclude other follicular disorders, and serum IGF-1 levels, though elevated, have no role in routine diagnostic workup.

From the histopathologic and laboratory findings discussed above, the clinical severity of acne is assessed using a range of validated instruments that guide treatment decisions and define endpoints in clinical trials. Standardized scoring is essential because therapeutic escalation, from topical monotherapy to systemic agents, depends on objective severity thresholds, and inconsistent outcome measures have historically hindered cross-trial comparisons ^[110]B2a.

Investigator-Assessed Severity Scales

The most widely used instrument in contemporary trials is the Investigator's Global Assessment (IGA), a static ordinal scale that grades overall acne severity from 0 (clear) to 4 (severe). Treatment success is typically defined as an IGA score of 0 or 1 (clear or almost clear) with a ≥2-grade improvement from baseline ^{[111]A1b[120]B2b}. In phase 3 studies of topical minocycline foam, this endpoint was met significantly more often with active treatment than vehicle (P <.05) ^[111]A1b. The IGA also serves as an inclusion criterion: moderate-to-severe acne is commonly defined as an IGA score ≥3 ^[60]A1b.

Alternative scales include the Investigator Static Global Assessment (ISGA), which is similar but uses a static snapshot rather than change from baseline ^[118]A1b, and the global acne severity grade used in earlier photodynamic therapy trials ^{[63]A1b[114]A1b}. Lesion counts, inflammatory, noninflammatory, and total, remain a core secondary endpoint and are reported as absolute change or percentage reduction ^{[112]A1a[117]A1b}. The Acne Severity Index (ASI) combines lesion counts with a weighting factor ^[115]C4. Despite this array, a systematic review found that variable attempts at validation and inconsistent reporting across 31 papers preclude a single recommended standard ^[110]B2a.

Patient-Reported Outcome Measures

Capturing the patient's perspective is critical because acne has substantial psychosocial impact. The Dermatology Life Quality Index (DLQI) is the most frequently used dermatology-specific PROM. In a prospective validation study of 53 adult females with mild-to-moderate facial acne treated with azelaic acid 15% gel, the mean baseline DLQI was 5.1 (SD 4.2), and the effect size in the 'Highly Improved' group was 0.66, supporting sensitivity to change ^[33]B2b. The Children's DLQI (CDLQI) is available for adolescents ^[119]A1b.

Disease-specific PROMs are less common. A systematic review of 54 development or validation studies identified 10 acne-specific PROMs, but only the Acne-Q and CompAQ had sufficient evidence for content validity and can currently be recommended for clinical studies ^[113]B2a. Despite this, PROMs were included in only 50% of acne RCTs from 2011 to 2021 and were rarely used as a primary outcome measure (7%) ^[109]A1a.

Risk Stratification and Clinical Decision-Making

Severity scoring directly gates therapy. Mild acne (IGA 1-2, few lesions) is typically managed with topical agents alone. Moderate acne (IGA 3) often requires combination topical therapy or oral antibiotics . Severe acne (IGA 4, nodulocystic) warrants systemic isotretinoin or other oral agents. The presence of scarring, postinflammatory hyperpigmentation, or significant psychosocial distress may escalate treatment regardless of lesion count. In clinical trials, the IGA and lesion counts are coprimary endpoints ^{[111]A1b[120]B2b}, and a ≥2-grade IGA improvement is the regulatory benchmark for efficacy ^[111]A1b.

Pearl: The IGA score and lesion counts are the twin pillars of acne severity assessment; a ≥2-grade IGA improvement defines treatment success in most pivotal trials, and PROMs like the DLQI and Acne-Q should be incorporated to capture the patient's lived experience.

Once severity is classified, acute management of severe or scarring acne requires prompt intervention to prevent permanent sequelae. This section outlines the stepwise approach for patients with severe nodulocystic acne, acne fulminans, or rapidly scarring disease.

Step 1: Initial Assessment and Severity Classification

Classify severity using the Investigator's Global Assessment (IGA) or similar scale. Severe acne is defined by IGA ≥3, presence of nodules, cysts, or extensive inflammatory lesions, and/or evidence of scarring or psychosocial burden ^[122]A1c. Acne fulminans, a rare, acute presentation with fever, arthralgias, and ulcerative lesions, requires immediate systemic therapy. Assess for contraindications to isotretinoin (pregnancy, hypersensitivity, hypertriglyceridemia ) and obtain baseline laboratory tests: complete blood count , lipid panel, and hepatic function ^[132]B2a.

Step 2: First-Line Intervention, Oral Isotretinoin

For severe acne, acne causing psychosocial burden or scarring, or failure of standard oral or topical therapy, the AAD 2024 guideline makes a strong recommendation for oral isotretinoin ^[122]A1c. The EuroGuiDerm 2026 update similarly prioritizes isotretinoin over systemic antibiotics for severe disease ^[130]A1c. A typical starting dose is 0.5 mg/kg/day, titrated to a cumulative dose of ≥120 mg/kg per single course ^[126]A1a. In a randomized trial, low-dose isotretinoin 10 mg daily combined with fish oil 1 g was noninferior to isotretinoin alone and preserved skin hydration and triglyceride control ^[60]A1b. For patients unable to tolerate systemic therapy, modified 5-aminolevulinic acid photodynamic therapy (M-PDT) offers a rapid onset of improvement (50% lesion reduction at 1 week vs 8 weeks with isotretinoin) with comparable overall efficacy and skin-limited side effects ^[123]A1b.

Step 3: Second-Line Options, Systemic Antibiotics and Hormonal Therapy

If isotretinoin is contraindicated or declined, systemic antibiotics are recommended. The AAD 2024 guideline makes a strong recommendation for oral doxycycline ^[122]A1c. Other tetracyclines (minocycline, sarecycline) and hormonal therapies (combined oral contraceptives , spironolactone ) receive conditional recommendations ^[122]A1c. A systematic review found no evidence of superiority among tetracyclines in reducing lesion counts ^[129]A1a. For moderate-to-severe acne, the most effective topical combination is a retinoid with clindamycin (mean difference 44.43%, 95% CrI 29.20-60.02%) ^[126]A1a. Combine systemic antibiotics with topical therapy and limit antibiotic duration to 3-4 months ^[122]A1c.

Step 4: Monitoring and Titration

For isotretinoin, a meta-analysis of 26 studies (1574 patients) found that mean changes in triglycerides (119.98 mg/dL), total cholesterol (184.74 mg/dL), and transaminases (ALT 21.77 U/L) did not meet high-risk criteria, and the proportion of patients with laboratory abnormalities was low ^[132]B2a. The evidence does not support monthly laboratory testing for standard doses in typical patients ^[132]B2a. However, baseline and follow-up at 1-2 months is prudent. For systemic antibiotics, monitor for gastrointestinal upset, photosensitivity, and vaginal candidiasis. If no significant improvement occurs after 3 months, escalate to isotretinoin or switch antibiotic class.

Step 5: Resolution and Transition

After completing isotretinoin (typically 6 months), transition to maintenance topical therapy (e.g., adapalene/benzoyl peroxide) to prevent relapse. For acute flares during treatment, intralesional corticosteroid injections for large nodules are recommended as a good practice statement ^[122]A1c. Dermocosmetics (cleansers, moisturizers, sunscreens) can improve tolerability and adherence as adjuncts ^[131]A1c.

What NOT to Do

• Do not use systemic antibiotic monotherapy without topical therapy; this promotes resistance ^[122]A1c.
• Do not combine isotretinoin with tetracyclines due to increased risk of pseudotumor cerebri.
• Do not perform monthly laboratory monitoring for isotretinoin in standard-risk patients; it is not supported by evidence ^[132]B2a.

Controversies and Guideline Disagreement

Pearl: For severe acne, initiate oral isotretinoin promptly (strong recommendation); laboratory monitoring can be less frequent than monthly based on meta-analytic evidence showing low rates of clinically significant abnormalities ^{[122]A1c[132]B2a}.

Having addressed acute management of severe acne and its complications, the long-term and definitive management of acne vulgaris follows a stepwise evidence ladder stratified by severity, with the goal of achieving sustained clearance while minimizing antibiotic exposure and side effects. The 2024 AAD guidelines and 2026 EuroGuiDerm update provide the framework, supported by network meta-analyses of topical and oral treatments ^{[122]A1c[130]A1c[126]A1a[112]A1a}.

Figure 1: Management algorithm for acne vulgaris (adapted from AAD 2024, EuroGuiDerm 2026, and NICE guidance ^{[122]A1c[130]A1c[126]A1a}).

Step 1: First-Line Topical Therapy for Mild-to-Moderate Acne

For mild-to-moderate acne, the AAD 2024 guideline makes a strong recommendation for benzoyl peroxide (BPO), topical retinoids, and topical antibiotics ^[122]A1c. Network meta-analysis of 179 RCTs found that the most effective topical option for mild-to-moderate acne is a combined retinoid with BPO (mean difference 26.16%, 95% CrI 16.75-35.36%) ^[126]A1a. A separate meta-analysis of 40 trials confirmed that adapalene/BPO is the most effective combination, with a 54% self-reported improvement versus 35% for BPO alone ^[43]A1a. For truncal acne, trifarotene 50 μg/g cream was safe and effective in two phase III trials, with significant reductions in both inflammatory and noninflammatory lesions at week 12 (P <.001) ^[61]A1b. The EuroGuiDerm update adds a conditional recommendation for clascoterone 1% cream as a novel topical androgen receptor inhibitor ^[130]A1c.

Step 2: Phototherapy and Procedural Options

Phototherapy serves as a second-line or adjunctive option. For mild-to-moderate acne, chemical peels (e.g., salicylic or mandelic acid) and photochemical therapy (combined blue/red light) are effective, with mean improvements of 39.70% and 35.36%, respectively ^[126]A1a. However, evidence quality is moderate to low. A systematic review of 25 trials found that blue-red light was more effective than topical 5% BPO in the short term, but results of light therapy alone were disappointing ^[127]A1a. For moderate-to-severe acne, photodynamic therapy (PDT) with 5-aminolevulinic acid or methyl aminolevulinate shows benefit, particularly for inflammatory lesions ^{[63]A1b[128]A1a}. A randomized trial comparing modified PDT (M-PDT) to low-dose isotretinoin (0.5 mg/kg/d) found that M-PDT had a faster onset (1 week to 50% improvement vs. 8 weeks) but at 6 months isotretinoin achieved higher effective rates (97.44% vs. 75.81%) ^[123]A1b. PDT is associated with pain, erythema, and pustular eruptions; patients with skin types I-III have lower risk of postinflammatory hyperpigmentation ^[124]A1b.

Step 3: Oral Therapy for Moderate-to-Severe Acne

When topical therapy is insufficient or disease is moderate-to-severe, oral systemic therapy is added. The AAD guideline gives a strong recommendation for oral doxycycline and conditional recommendations for oral minocycline , sarecycline , combined oral contraceptive pills, and spironolactone ^[122]A1c. A meta-analysis of 32 RCTs found that at 6 months, oral antibiotics and oral contraceptives had equivalent efficacy (weighted mean inflammatory lesion reduction: antibiotics 57.9%, OCPs 61.9%) ^[133]A1a. The EuroGuiDerm update specifies that systemic antibiotics should be limited to 3-4 months to minimize resistance ^[130]A1c. For women, hormonal therapy (OCPs or spironolactone) is a preferred long-term alternative to systemic antibiotics ^[133]A1a.

Step 4: Isotretinoin for Severe or Refractory Acne

Oral isotretinoin is the most effective treatment for severe, scarring, or psychosocially burdensome acne, and for acne that has failed standard therapy ^[122]A1c. A network meta-analysis reported that isotretinoin at a total cumulative dose ≥120 mg/kg per single course produced a 58.09% reduction in lesion counts (95% CrI 36.99-79.29%) ^[126]A1a. The EuroGuiDerm update prioritizes isotretinoin over systemic antibiotics for severe acne ^[130]A1c. Low-dose isotretinoin (10 mg daily) combined with fish oil 1 g daily was noninferior to low-dose isotretinoin alone and may preserve skin hydration and control triglyceride levels ^[60]A1b. Modified PDT offers a faster onset but lower long-term efficacy compared to isotretinoin ^[123]A1b.

Step 5: Maintenance Therapy and Dermocosmetics

After achieving clearance, maintenance therapy with a topical retinoid (e.g., adapalene or trifarotene) is recommended to prevent relapse. The AAD guideline recommends combining topical therapies with multiple mechanisms of action and limiting systemic antibiotic use ^[122]A1c. Dermocosmetics, cleansers, moisturizers, and sunscreens with acne-targeting ingredients, can be used as monotherapy in mild acne or as adjuncts to improve tolerability and enhance efficacy ^[131]A1c. Expert consensus recommends integrating dermocosmetics into the acne management algorithm to improve barrier function, reduce oiliness, and maintain clearance ^[131]A1c.

Controversies and Guideline Disagreement

Pearl: For mild-to-moderate acne, initiate a fixed topical combination (retinoid + BPO) as first-line; for moderate-to-severe acne, add an oral tetracycline or hormonal therapy, but limit systemic antibiotics to 3-4 months and escalate to isotretinoin if response is inadequate, scarring occurs, or psychosocial burden is significant ^{[122]A1c[126]A1a[130]A1c}.

Building on the therapeutic ladder outlined above, the evolution of acne treatment over the past four decades reveals a progressive shift from empirical polypharmacy to evidence-based, mechanism-targeted regimens. Landmark trials and updated guidelines have refined the role of each modality, while some once-common approaches have been abandoned due to lack of efficacy or safety concerns.

The Rise of Topical Retinoids and Antibiotics (1980s-1990s)

The modern era began with the development of topical retinoids. A double-blind trial comparing CD 271 (adapalene) 0.1% gel with tretinoin 0.025% gel found that 0.1% CD 271 gel was as effective as tretinoin in reducing total comedone counts (83% reduction for both) and significantly superior in reducing inflammatory lesions (69% vs 50%, P<0.05) ^[140]A1b. Fixed-dose combinations soon followed: a clindamycin 1%/tretinoin 0.025% gel (Velac) applied once daily was superior to clindamycin lotion twice daily in reducing overall acne severity scores (P=0.01) and had a more rapid onset, 77% of patients on the combination achieved 50% lesion reduction by day 60 vs 56% on clindamycin alone (P=0.003) ^[141]A1b.

The Era of Combination Therapy (2000s-2010s)

Benzoyl peroxide (BPO) emerged as a non-antibiotic antimicrobial partner. A phase III trial in Japanese patients demonstrated that clindamycin phosphate 1.2%/BPO 3.0% fixed-dose gel once daily was noninferior to clindamycin twice daily and superior in reducing total lesion counts (difference -10.3; P<0.01) ^[47]A1b. The challenge of chemical instability between BPO and tretinoin was overcome by microencapsulation. Two phase III trials of encapsulated BPO 3%/tretinoin 0.1% cream (E-BPO/T) showed significantly higher IGA success rates (38.5% and 25.4%) vs vehicle (11.5% and 14.7%) ^[136]A1b.

Systemic Antibiotics: From Long Courses to Short, Targeted Use

Oral antibiotics have long been a mainstay, but their prolonged use is now discouraged. The 2024 AAD guideline makes a strong recommendation for oral doxycycline and conditionally recommends minocycline and sarecycline ^[122]A1c. A phase III trial of FMX101 4% topical minocycline foam demonstrated significantly greater reductions in inflammatory lesions and treatment success vs vehicle at week 12 ^[138]A1b. The 2026 EuroGuiDerm update specifically addressed appropriate duration for systemic antibiotic therapy, emphasizing limitation to avoid resistance ^[130]A1c.

Isotretinoin: The Game Changer

Oral isotretinoin remains the most effective therapy for severe acne. The AAD guideline gives a strong recommendation for isotretinoin in acne that is severe, causing psychosocial burden or scarring, or failing standard therapy ^[122]A1c. Low-dose regimens have been explored: a randomized trial found that low-dose isotretinoin (10 mg) combined with fish oil (1 g) was noninferior to isotretinoin alone and associated with better preservation of skin hydration and triglyceride control ^[60]A1b. Modified 5-aminolevulinic acid photodynamic therapy (M-PDT) was compared with low-dose isotretinoin (0.5 mg/kg/d for 6 months) in a multicenter trial: M-PDT had faster onset (1 week vs 8 weeks to 50% improvement) and comparable overall efficacy, but isotretinoin had higher systemic side effects (70.67% experienced hepatotoxicity) ^[123]A1b.

Hormonal Therapies

Spironolactone , an androgen receptor blocker, was evaluated in a double-blind trial of 36 patients with severe acne. Spironolactone (50-200 mg daily) reduced sebum excretion in all female subjects, with maximum clinical benefit at doses of 150-200 mg ^[139]A1b. The AAD guideline now conditionally recommends spironolactone and combined oral contraceptive pills ^[122]A1c.

Photodynamic Therapy and Lasers

Photodynamic therapy (PDT) has been investigated as an alternative for moderate-to-severe acne. Methyl aminolaevulinate (MAL)-PDT (160 mg/g) produced a median 54% reduction in inflammatory lesions vs 20% with placebo (P=0.0006) ^[114]A1b. A higher-concentration formulation (MAL 80 mg/g) with red light achieved 44% treatment success vs 26% vehicle (P=0.013) ^[62]A1b. However, MAL-PDT was associated with severe pain and adverse effects; 7 of 21 patients did not receive a second treatment due to adverse effects ^[63]A1b. Chlorophyll-a PDT showed significant reductions in lesion counts and sebum levels compared with light alone ^[93]A1b. The 1450-nm diode laser produced 75% reduction in mean acne lesion counts after 3 treatments, maintained at 12 months ^[137]A1b. In contrast, pulsed-dye laser (PDL) as an adjuvant to clindamycin/BPO gel showed no significant benefit over topical therapy alone ^[118]A1b.

What Was Abandoned and Why

Long-term systemic antibiotic therapy (months to years) has been largely abandoned due to antimicrobial resistance and lack of evidence for sustained benefit; guidelines now recommend limiting antibiotic duration ^[130]A1c. PDL is not supported as an adjunctive treatment ^[118]A1b. Older treatments such as tetracycline monotherapy and high-dose vitamin A have been replaced by more effective and safer options.

The Modern Guideline Era

The 2024 AAD guideline provides 18 evidence-based recommendations, including strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline ^[122]A1c. The 2026 EuroGuiDerm update prioritized three key clinical questions: isotretinoin vs systemic antibiotics, duration of antibiotic therapy, and hormonal treatments including spironolactone and new topicals like trifarotene and clascoterone ^[130]A1c. These guidelines ground current practice in a robust evidentiary framework, ensuring that each step of the therapeutic ladder is supported by randomized trial data.

Pearl: The evolution of acne treatment is a story of progressive refinement: from long, untargeted antibiotic courses to short, mechanism-specific regimens, and from empirical polypharmacy to fixed-dose combinations validated by phase III trials. The 2024 AAD and 2026 EuroGuiDerm guidelines now provide a clear evidence-based framework that clinicians should follow to optimize outcomes and minimize harm.

Building on the evolution of acne therapies, procedural interventions now offer alternative or adjunctive options for patients who cannot tolerate or do not respond to conventional treatments. These modalities range from photodynamic therapy (PDT) and laser/light devices to chemical peels, each with distinct evidence profiles and side-effect considerations.

Photodynamic Therapy

Photodynamic therapy (PDT) combines a photosensitizer (aminolevulinic acid [ALA] or methyl aminolevulinate [MAL]) with a light source to generate reactive oxygen species that target sebaceous glands and inflammatory pathways. A systematic review of 16 randomized controlled trials (RCTs) found that PDT produced the most consistent short-term improvements in inflammatory acne, with up to 68% reduction in lesions ^[145]A1a. However, the quality of evidence is limited by small sample sizes and short follow-up.

MAL-PDT has been evaluated in several vehicle-controlled trials. In a double-blind RCT of 153 patients with severe acne (IGA score 4), MAL 80 mg/g applied for 1.5 hours under occlusion followed by red light (635 nm, 37 J/cm²) reduced inflammatory lesions by a mean of -15.6 vs -7.8 with vehicle (P=0.006; mean percentage change -37.3% vs -16.2%). Treatment success (≥2-grade IGA improvement) was 44% vs 26% (P=0.013), yielding an NNT of 6 for one additional success ^[62]A1b. Noninflammatory lesions did not decrease significantly. Pain was manageable with brief pauses in illumination ^[62]A1b. Another RCT (n=30) reported a median reduction in inflammatory lesions of 54% with MAL-PDT vs 20% with placebo at week 12 (P=0.0006) ^[114]A1b. A third trial (n=21) showed a 68% reduction from baseline in inflammatory lesions vs no change in controls (P=0.0023), but 7 of 21 patients did not receive the second treatment due to severe pain, erythema, pustular eruptions, and epithelial exfoliation ^[63]A1b.

ALA-PDT has been compared directly with MAL-PDT in a split-face study (n=15). Both achieved a 59% decrease in inflammatory lesions at 12 weeks, with no significant difference in efficacy, but ALA-PDT caused more prolonged and severe adverse effects ^[142]A1b. Modified ALA-PDT (M-PDT), up to 5 weekly sessions following manual comedone extraction, was compared with oral isotretinoin 0.5 mg/kg/day for 6 months in a multicenter RCT (n=152). At 1 month, the overall effective rate was 67.74% with M-PDT vs 10.26% with isotretinoin (NNT = 2 for early response). However, 1 month after treatment completion, isotretinoin was superior (75.81% vs 97.44%). Time to 50% lesion improvement was 1 week with M-PDT vs 8 weeks with isotretinoin. Systemic side effects (e.g., hepatotoxicity) occurred in 70.67% of the isotretinoin group, whereas M-PDT side effects were skin-limited ^[123]A1b.

Practical parameters for PDT: short-contact application (90 minutes or less) of ALA or MAL, using a noncoherent light source at 2-4 week intervals for a total of 2-4 treatments. Papulopustular acne responds best, and all Fitzpatrick skin types are eligible, though types I-III have lower risk of postinflammatory hyperpigmentation. Remission can last 3 months to 1 year ^[124]A1b.

Alternative photosensitizers have been explored to reduce side effects. Chlorophyll-a PDT (8 sessions over 4 weeks) significantly reduced lesion counts, severity grades, and sebum levels compared with LED phototherapy alone in 24 Asian subjects ^[93]A1b. Indocyanine green (ICG) and indole-3-acetic acid (IAA) PDT, each combined with appropriate light (805 nm and 520 nm, respectively), both produced significant reductions in inflammatory and noninflammatory lesions and sebum secretion over 5 weekly treatments, with minimal adverse effects ^[149]B2b.

Laser and Light Therapies

Pulsed dye laser (PDL) has conflicting evidence. A meta-analysis of 6 studies found that PDL was not superior to control for acne severity score (SMD -0.285; 95% CI -0.886 to 0.317). However, single-arm analyses showed significant improvement, particularly when 4 or more sessions or a longer pulse duration were used; comedone counts also decreased (SMD -0.596; 95% CI -1.137 to -0.054) ^[150]A1a. The AAD systematic review assigned PDL a recommendation grade B for acne vulgaris ^[41]A1a.

1450-nm diode laser targets sebaceous glands thermally. In a dose-response study (n=20, Fitzpatrick II-VI), 3 treatments at 14 or 16 J/cm² reduced inflammatory lesions by 42.9% after one treatment and 75.1% after three, with persistent 76.1% reduction at 12 months ^[137]A1b. However, a split-face RCT (n=32) found no difference between treated and control sides in lesion count or acne grade at 4 weeks or 12 months; both sides improved, suggesting a possible systemic effect ^[144]A1b. Moderate evidence supports the diode laser ^[147]B2a.

1726-nm laser is a newer device selectively absorbed by sebaceous glands. In a prospective open-label study of 104 subjects (Fitzpatrick II-VI) receiving 3 treatments, ≥50% reduction in inflammatory lesions was 32.6% at 4 weeks, rising to 79.8% at 12 weeks and 87.3% at 26 weeks. The proportion of subjects clear or almost clear increased from 0% at baseline to 9%, 36.0%, and 41.8% at 4, 12, and 26 weeks, respectively. No serious adverse events occurred; treatments were well tolerated without anesthesia, and outcomes were similar across all skin types ^[148]B2b.

1064-nm Nd:YAG laser with topically applied carbon suspension (dual mode: quasi-long pulse and Q-switched) was evaluated in a split-face RCT (n=22). After 3 sessions at 2-week intervals, inflammatory lesions decreased by 58.6% on the treated side vs a 5% increase on the untreated side; noninflammatory lesions decreased by 52.4%. Histopathology showed reduced inflammation and decreased immunostaining for IL-8, MMP-9, TLR-2, NF-κB, and TNF-α. Side effects were limited to transient erythema ^[21]A1b.

Intense pulsed light (IPL) has moderate evidence. A best-evidence synthesis found moderate support for IPL (400-700 and 870-1200 nm) ^[147]B2a. IPL-assisted PDT appears superior to IPL alone ^[145]A1a.

Blue-red light therapy: A systematic review of 25 trials found that blue-red light was more effective than topical 5% benzoyl peroxide cream in the short term, but overall results for light alone were disappointing ^[127]A1a. The Cochrane review (71 RCTs, 4211 participants) concluded that most light-alone trials showed little or no clinically significant effect, with the exception of blue light, blue-red light, and infrared when multiple treatments were used ^[128]A1a.

Chemical Peels and Other Procedures

Glycolic acid peels (10-40%) have strong evidence for efficacy in acne, based on a best-evidence synthesis of high-quality trials ^[147]B2a. Amino fruit acid (20-60%) has moderate evidence ^[147]B2a. Chemical peels are typically used as adjuncts to topical therapy.

Fractional microneedling radiofrequency has shown significant reduction in acne lesions in some studies, but the evidence is limited by low methodological quality ^[147]B2a.

Controversies and Guideline Disagreement

Pearl: For patients with moderate-to-severe acne who cannot tolerate or decline isotretinoin, PDT with short-contact ALA or MAL offers a rapid-onset alternative (NNT = 2 for early response), but counsel patients about significant pain and post-treatment erythema; the 1726 nm laser provides durable improvement across all skin types without anesthesia.

Following procedural interventions, the clinician must remain vigilant for the psychosocial and treatment-related harms that accompany acne. Psychiatric comorbidities are among the most consequential. A meta-analysis of 42 studies found a significant association of acne vulgaris with depression (r = 0.22 [95% CI 0.17-0.26, ]) and anxiety (r = 0.25 [95% CI 0.19-0.31, ]) ^[44]B2a. Suicidal ideation is more common in those with severe compared with mild acne ^[42]A1a. These findings support aggressive treatment and consideration of psychiatric screening or referral ^[44]B2a.

Systemic Comorbidities

Acne severity correlates with pubertal maturity, and in a multiethnic cohort of 13-year-olds, visible acne prevalence was 62% in girls and 45% in boys, with moderate-to-severe disease in 14% and 9%, respectively ^[49]B3b. Darker skin (Fitzpatrick V-VI) and overweight in boys were independent risk factors for more severe acne ^[49]B3b. The heritability of acne is almost 80% in first-degree relatives ^[42]A1a. Acne vulgaris is also a common comorbidity in pediatric hidradenitis suppurativa , with a pooled prevalence of 43% (95% CI 21-65) ^[45]B2a.

Treatment-Related Harms

Isotretinoin, the first-line therapy for severe acne, produces predictable laboratory changes. In a meta-analysis of 26 studies (1574 patients), mean on-treatment values were triglycerides 119.98 mg/dL, total cholesterol 184.74 mg/dL, LDL 109.23 mg/dL, HDL 42.80 mg/dL, AST 22.67 U/L, and ALT 21.77 U/L; the proportion of patients with clinically significant abnormalities was low, and the authors concluded monthly laboratory testing is not supported for standard patients ^[132]B2a. Mucocutaneous effects are universal: nearly 100% of patients develop cheilitis and xerosis, and retinoid dermatitis is more common with cumulative doses ≥220 mg/kg (53.8% vs 31.6%) ^[154]B3b. The same high-dose regimen reduced relapse at 12 months (26.9% vs 47.4%) without increasing other adverse effects ^[154]B3b. Isotretinoin may reduce height velocity (-0.12 cm/month; CI -0.21 to -0.04, P =.005) but is not associated with negative effects on final adult height (-0.67 cm; CI -2.21 to 0.87) ^[74]B3b. Fish oil supplementation (1 g daily) combined with low-dose isotretinoin (10 mg) preserves skin hydration and blunts triglyceride elevation ^[60]A1b. In a comparative trial, 70.67% of patients on oral isotretinoin 0.5 mg/kg/d experienced systemic side effects such as hepatotoxicity, whereas side effects were skin-limited in the modified photodynamic therapy group ^[123]A1b.

Topical therapies also carry risks. Clindamycin 1.2%-benzoyl peroxide 3% gel caused adverse drug reactions in 24.0% (once daily) and 35.1% (twice daily) of Japanese patients, versus 9.0% with clindamycin alone ^[47]A1b. Benzoyl peroxide with adapalene or clindamycin leads to slightly higher withdrawal rates (2.5% and 2.7%, respectively) than monotherapy ^[43]A1a. Minocycline use is associated with lupus erythematosus (adjusted HR 3.11; 95% CI 1.77-5.48), an uncommon but serious event ^[153]B3b. Photodynamic therapy with methyl aminolaevulinate causes moderate to severe pain during treatment and severe erythema, pustular eruptions, and epithelial exfoliation; 7 of 21 patients did not receive the second treatment due to adverse effects ^[63]A1b.

Cutaneous Sequelae

Postinflammatory hyperpigmentation disproportionately affects Black individuals, and scarring is a frequent long-term consequence that drives the need for early effective treatment ^[42]A1a.

Complication Table

Pearl: Screen all patients with moderate-to-severe acne for depression and anxiety; the association is moderate but actionable, and treatment may alleviate both skin and psychiatric symptoms ^[44]B2a.

Beyond the immediate physical and psychosocial burden, the natural history of acne is characterized by a chronic relapsing course that extends well beyond adolescence. Acne vulgaris contributes 0.29% to the global burden of disease measured in disability-adjusted life years (DALYs) ^[34]B3b, and skin diseases rank as the fourth leading cause of disability worldwide when mortality is excluded ^[34]B3b. Understanding the expected trajectory of the disease, including rates of spontaneous remission, response to therapy, and risk of relapse, is essential for setting realistic patient expectations and planning long-term management.

Natural History and Remission

Acne vulgaris affects approximately 85% of adolescents and often persists into adulthood ^[76]A1c. In primary care, two-thirds (66.1%) of patients who have a new acne consultation have no further acne consultations in the subsequent year ^[156]B3b, suggesting that many cases either resolve or are managed without follow-up. However, this pattern may also reflect suboptimal longitudinal care: 60.1% of patients prescribed an acne-related medication receive no further prescription in the following 90 days, and 38.6% receive none in the following year, despite most prescriptions being for 2 months or less ^[156]B3b.

With active treatment, remission rates are substantially higher. After three sessions of 1450-nm diode laser, mean acne lesion counts are reduced by 75.1% (14 J/cm²) and 70.6% (16 J/cm²), with persistent reduction of 76.1% and 70.5% respectively at 12-month follow-up ^[137]A1b. Photodynamic therapy (PDT) produces remission lasting at least 3 months to a year ^[124]A1b; a systematic review of 4340 patients found that all treated patients achieved a partial response, with no complete or lack of response reported ^[159]A1a. Visible light therapy yields partial remission in 92% of patients, with an average total lesion count improvement of 43% at week 4 ^[162]B2a.

Relapse and Recurrence

Relapse after treatment discontinuation is common. In a meta-analysis, conventional-dose isotretinoin (0.5-1.0 mg/kg/day to a cumulative dose of 120-150 mg/kg) improves the odds of prolonged remission compared with low-dose regimens ^[163]B2a. Low-dose isotretinoin (0.1-0.3 mg/kg/day for more than 6 months) may have fewer side effects but higher recurrence rates ^[164]B2a. Tanshinone capsules reduce acne recurrence rates (risk ratio 0.44, 95% CI 0.34-0.57) ^[158]A1a. For acne fulminans, only 33.3% of patients achieve remission after first-line treatment with systemic corticosteroids alone or in combination ^[66]C4.

Long-term Scarring Outcomes

Maintenance therapy after remission of inflammation is strongly recommended to prevent atrophic scarring. In a 24-week randomized trial, the treatment success rate (maintaining inflammatory lesions ≤10) was 89.2% with adapalene 0.1%/benzoyl peroxide 2.5% gel, 87.5% with benzoyl peroxide 2.5% gel alone, and only 47.4% in the control group (P = 0.0006 for both active groups vs control) ^[167]A1b. Atrophic scar counts improved significantly from baseline in both active groups at week 24 (P = 0.0004 and P < 0.0001), while the control group showed significant worsening in scar area, volume, and maximum depth ^[167]A1b. These data underscore that without continued treatment, scarring progresses.

Factors Influencing Prognosis

Prognosis is influenced by disease severity, adherence, and treatment modality. Patients with moderate-to-severe acne (25.6% of those treated with PDT in one systematic review) ^[159]A1a may require more intensive therapy. Systemic antibiotic treatment (e.g., minocycline 100 mg twice daily for 4 weeks) reduces Cutibacterium acnes by 1.4-fold, but microbiota recovery is variable and may be incomplete ^[96]C4. Nd:YAG laser (1064 nm) has a more prolonged therapeutic effect than intralesional botulinum toxin type A or tranexamic acid, with lower recurrence rates at 3-month follow-up ^{[166]A1b[168]A1b}.

Pearl: Maintenance therapy with adapalene/benzoyl peroxide or benzoyl peroxide alone after achieving remission reduces the risk of relapse and prevents progression of atrophic scarring; without it, nearly half of patients relapse within 24 weeks and scar parameters worsen significantly ^[167]A1b.

While prognosis is generally favorable with appropriate therapy, treatment decisions must be tailored in special populations where standard regimens may be unsafe or inadequately studied.

Pediatrics

Acne often begins in adolescence, with severity correlating with pubertal maturity ^[42]A1a. Many topical and systemic treatments have been studied in pediatric populations. Trifarotene 50 μg/g cream and encapsulated benzoyl peroxide 3%/tretinoin 0.1% cream are approved for use in patients aged 9 years and older ^{[61]A1b[136]A1b}. For patients aged 12 years and older, options include dapsone gel 5% ^[170]A1b, clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel ^[171]A1b, minocycline 4% foam ^{[111]A1b[138]A1b}, and adapalene gel 0.3% ^[169]A1b. Oral antibiotics such as lymecycline 300 mg daily have been studied in combination with topical adapalene/BPO in adolescents ^[152]A1b. Pediatric patients with acne are at increased risk for comorbidities; in a meta-analysis of pediatric hidradenitis suppurativa , acne vulgaris was present in 43% (95% CI 21-65) ^[45]B2a. Early recognition and treatment are important to prevent scarring and psychosocial impact.

Pregnancy

Acne management during pregnancy requires careful avoidance of teratogenic agents. The EuroGuiDerm guideline provides updated recommendations on treatment considerations during pregnancy, including the safety of benzoyl peroxide, selection of systemic antibiotic therapy, and the use of hormonal treatments ^[130]A1c. Topical therapies considered relatively safe include azelaic acid and topical erythromycin, though specific evidence from the provided references is limited. Systemic antibiotics such as penicillins and cephalosporins are generally preferred over tetracyclines. The guideline also addresses isotretinoin dosing strategies and the use of spironolactone and hormonal contraceptives ^[130]A1c. For breastfeeding , data are sparse; topical treatments with minimal systemic absorption are preferred.

Elderly

Acne in the elderly is less common but may present as persistent or late-onset acne. Clinical trial data in patients over 45 years are lacking; most studies enrolled patients up to age 45 ^{[64]A1b[172]A1b}. Treatment should be individualized, with attention to skin barrier function and comorbidities. Topical retinoids and benzoyl peroxide may be used with caution due to increased skin sensitivity. Systemic antibiotics should be chosen with consideration of renal function and drug interactions.

Immunocompromised

No specific studies in immunocompromised patients with acne were identified in the provided literature. Standard acne treatments should be used with caution, particularly systemic antibiotics and immunosuppressive agents. Consultation with the managing specialist is recommended.

Pearl: In pediatric acne, trifarotene and encapsulated BPO/tretinoin are approved from age 9; for pregnancy, consult the EuroGuiDerm guideline for safe treatment options ^[130]A1c.

Beyond pregnancy-specific considerations, prevention of acne flares and long-term sequelae requires a structured approach spanning primary prevention, maintenance therapy, and targeted surveillance.

Primary Prevention

Avoidance of known triggers is the first step. Patients should be counseled to use non-comedogenic skincare and cosmetic products, and to avoid heavy oils, pomades, and prolonged mask use that can induce acne mechanica ^[76]A1c. Photoprotection is essential: broad-spectrum sunscreen with SPF ≥ 50, water-based, non-comedogenic, and preferably tinted with iron oxides to block visible light, which exacerbates post-inflammatory hyperpigmentation (PIH) in skin of color ^[76]A1c. The 2024 international expert consensus recommends sunscreens as part of a basic dermocosmetic routine for all acne patients ^[131]A1c. In a phase IV study, a skincare regimen including sunscreen combined with trifarotene improved acne-induced hyperpigmentation and was well tolerated across all skin phototypes ^[80]A1b.

Secondary Prevention (Maintenance Therapy)

Acne is a chronic disease; maintenance therapy after initial clearance prevents relapse and reduces scarring. The 2017 Japanese Dermatological Association guidelines recommend limiting antimicrobial treatment to the acute inflammatory phase (up to ~3 months) and using benzoyl peroxide (BPO), adapalene, or a fixed-dose combination gel of 0.1% adapalene/2.5% BPO for maintenance to avoid antimicrobial resistance ^[174]A1c. A 6-month randomized trial showed that adapalene-BPO gel maintained ≥50% improvement in 78.9% of patients vs. 45.8% with vehicle (P < 0.001); the time to 25% relapse was 175 days vs. 56 days ^[151]A1b. A meta-analysis confirmed that adapalene-BPO yields superior success rates and satisfaction compared with vehicle ^[184]B2a. Adapalene 0.1% gel alone also maintained improvement after oral lymecycline, with a maintenance rate of 84.7% vs. 63.5% ^[182]A1b. For patients with moderate acne, clindamycin phosphate 1.2%/BPO 3.75% gel used for 24 weeks achieved 93.8% reduction in inflammatory lesions and 72% of patients were clear/almost clear ^[178]A1b. Topical dapsone 5% gel maintained response in 82% of patients after doxycycline discontinuation ^[179]A1b. Maintenance therapy also prevents atrophic scarring: in a 24-week study, adapalene/BPO and BPO alone significantly reduced scar progression compared with no treatment ^[167]A1b. Dermocosmetics (cleansers, moisturizers, sunscreens) are recommended as adjuncts to maintain clearance and improve tolerability ^{[131]A1c[76]A1c}.

Screening and Surveillance

Given the increased risk of depression and anxiety in acne patients (r = 0.22 and 0.25, respectively), clinicians should consider psychiatric screening or referral ^[44]B2a. For preadolescent children with acne, a focused history and physical examination is sufficient; hand X-ray for bone age is a useful screening test if signs of early puberty are present ^[185]C4. Regarding isotretinoin, attorney-initiated reports have inflated the pharmacovigilance signal for inflammatory bowel disease in the FAERS database (signal inflation factor 5.82), but no causal association has been proven ^[175]D5.

Vaccine Considerations

Experimental vaccines targeting Cutibacterium acnes CAMP factor have shown promise in murine models and ex vivo human skin, reducing bacterial colonization and IL-8/IL-1β production ^{[106]D5[107]D5}. However, no acne vaccine is currently approved for clinical use.

Patient Education

Patients should be educated on proper skincare: gentle pH-balanced cleansers, non-comedogenic moisturizers, and daily sunscreen. Adherence to maintenance therapy is critical to prevent relapse and scarring. Clinicians should address psychosocial impact and provide realistic expectations about treatment timelines.

Pearl: Maintenance therapy with a topical retinoid (adapalene) plus benzoyl peroxide, continued for at least 6 months after initial clearance, reduces relapse risk by approximately 33% and prevents atrophic scar progression ^{[151]A1b[167]A1b}.